Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
Développer la qualité dans le champ sanitaire, social et médico-social
Logo
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Recherche
  • icone plus

  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Établissements de santé

1 result

  • Language : Français
  • Active substance : galantamine
Filter
Topic
  • Diagnostic and therapeutic techniques (1)
  • Plus ...
    • Drug therapy (1)
  • Diseases and conditions (1)
  • Plus ...
    • Mental disorders and behavioural conditions (1)
    • Plus ...
      • Alzheimer’s disease and mental disorders (1)
    • Nervous system diseases (1)
    • Plus ...
      • Neurodegenerative diseases (1)
      • Central nervous system diseases (1)
  • Population groups (1)
  • Plus ...
    • Geriatrics (1)
Content type
  • Drugs, devices and medical acts (1)
  • Plus ...
    • Medicine (1)
Langue
  • Français (1)
Substance active
  • galantamine (1)
More filter Other Filter Icon
Search Export

Drugs, devices and medical acts - 1 result

  • REMINYL (galantamine bromhydrate)

    Medicine - Posted on 25/1/2017 - Mis à jour le 12/6/2019
    Add to my selection

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
0HhYEUFFrAFGAFqD